Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zimmer Biomet HoldingsXSWX:ZBH 77 Equity-to-Asset is 0.55 as of Jun. 2026, which is 6% above its 10-year median of 0.52. GuruFocus rates XSWX:ZBH with a GF Score™ of 77/100 and a GF Value™ of CHF100.56. The stock has 4 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks worse than 61.97% on this metric.
The historical rank and industry rank for Zimmer Biomet Holdings's Equity-to-Asset or its related term are showing as below:
XSWX:ZBH'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36 Med: 0.52 Max: 0.59
Current: 0.55
During the past 13 years, the highest Equity to Asset Ratio of Zimmer Biomet Holdings was 0.59. The lowest was 0.36. And the median was 0.52.
XSWX:ZBH's Equity-to-Asset is ranked worse than 61.97% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs XSWX:ZBH: 0.55
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Zimmer Biomet Holdings Equity-to-Asset Related Terms
Zimmer Biomet Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Zimmer Biomet Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZBH vs STE, PEN, PODD: Equity-to-Asset Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Zimmer Biomet Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings (XSWX:ZBH) has a Equity-to-Asset of 0.55 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zimmer Biomet Holdings and its competitors. This is near median its historical median of 0.52. Over the past decade, Zimmer Biomet Holdings' Equity-to-Asset has ranged from 0.36 to 0.59. According to the industry distribution chart, Zimmer Biomet Holdings ranks #528 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 62%.
Is Zimmer Biomet Holdings' Equity-to-Asset too high?
Zimmer Biomet Holdings' current Equity-to-Asset of 0.55 is near median its 10-year median of 0.52. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 0.59. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Zimmer Biomet Holdings' value of 0.55 is 14.7% below this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #528 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Equity-to-Asset compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #528 out of 852 companies for Equity-to-Asset. This places Zimmer Biomet Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.65. Zimmer Biomet Holdings' value of 0.55 is 14.7% below this benchmark. Historically, Zimmer Biomet Holdings' own Equity-to-Asset has ranged from 0.36 to 0.59 over the past decade. While the company's 10-year median is 0.52 vs. the industry median of 0.65, Zimmer Biomet Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current Equity-to-Asset of 0.55 is 14.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current Equity-to-Asset is 0.55, which is near median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current Equity-to-Asset of 0.55. The stock's GF Value™ is CHF100.56, compared to a current price of CHF78.50 — trading 21.9% below its estimated fair value. The current Equity-to-Asset is 0.55, which is near median its 10-year median of 0.52 and 14.7% below the Medical Devices & Instruments industry median of 0.65. Zimmer Biomet Holdings' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Equity-to-Asset is 0.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF78.50 is trading 21.9% below its estimated GF Value™ of CHF100.56.
Key valuation signals for XSWX:ZBH:
Equity-to-Asset: 0.55 (near median its 10-year median of 0.52)
GF Value™: CHF100.56 vs. price of CHF78.50 (21.9% below fair value)
Industry Position: 14.7% below the Medical Devices & Instruments median (#528 of 852)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
77GF Score
Get the complete analysis for XSWX:ZBH
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
